Colistimethate Sodium for Injection Market by Indication (Bloodstream Infection, Lower Respiratory Tract Infection, Skin And Soft Tissue Infection), Dosage Form (Lyophilized Powder, Ready To Use Solution), Patient Population, Route Of Administration, End
Description
The Colistimethate Sodium for Injection Market was valued at USD 50.54 million in 2025 and is projected to grow to USD 58.89 million in 2026, with a CAGR of 11.81%, reaching USD 110.43 million by 2032.
A comprehensive introduction that outlines the clinical role, formulation choices, and delivery considerations shaping colistimethate sodium injection utilization in modern care settings
Colistimethate sodium for injection occupies a critically important position in the therapeutic arsenal against multidrug-resistant Gram-negative infections. Clinically, it is deployed in severe bloodstream infections, complicated lower respiratory tract infections, challenging skin and soft tissue infections, and select urinary tract infections where alternative agents are ineffective or contraindicated. As resistance to contemporary beta-lactams and carbapenems has risen, clinicians have returned to older polymyxin-class agents like colistimethate sodium, balancing potent antibacterial activity against known safety considerations such as nephrotoxicity and neurotoxicity.
From a formulation and delivery perspective, the injectable product exists in multiple dosage forms and routes, which shape hospital administration practices and procurement preferences. Intravenous administration is predominant for systemic infections, whereas inhalation is increasingly used as an adjunctive approach in ventilator-associated complications. Additionally, distinctions between lyophilized powder that requires reconstitution and ready-to-use solutions influence pharmacy workflow and bedside efficiency. Taken together, these clinical, formulation, and delivery characteristics define the decision criteria for clinicians, pharmacy leaders, and purchasing groups evaluating the role of colistimethate sodium within treatment protocols.
How clinical resistance dynamics, stewardship protocols, and sterile manufacturing advances are reshaping therapeutic practice and procurement strategies for colistimethate sodium injection
The therapeutic and commercial landscape for colistimethate sodium injection is undergoing transformative shifts driven by antimicrobial resistance trends, evolving hospital practice standards, and innovations in sterile injectable manufacturing. Clinically, the expanding prevalence of carbapenem-resistant Enterobacterales and multidrug-resistant Acinetobacter species has elevated reliance on polymyxin-class therapies as salvage or combination regimens, prompting more frequent stewardship-led protocols that standardize dosing and monitoring to mitigate toxicity risks.
Operationally, hospitals and integrated delivery networks are accelerating adoption of ready-to-use infusion preparations and automated compounding technologies to reduce preparation time, limit contamination risk, and improve dosing accuracy. Concurrently, supply chain modernization - including strategic dual-sourcing, regional sterile fill-finish partnerships, and increased transparency around API origins - is reshaping procurement strategies. Regulatory scrutiny and post-marketing safety surveillance are also intensifying, with stakeholders demanding robust real-world evidence and pharmacovigilance data to support formulary decisions and optimize therapeutic pathways.
Analysis of how 2025 United States tariff changes have compounded supply chain, sourcing, and procurement dynamics affecting colistimethate sodium injection availability and commercial strategies
Cumulative adjustments to United States tariff schedules and related trade policy changes enacted through 2025 have created a layered impact on the injectable pharmaceuticals ecosystem that includes colistimethate sodium. Increased duties on select active pharmaceutical ingredients and intermediates, combined with higher freight and compliance-associated costs, have elevated landed costs for some producers that rely on globally distributed supply chains. As a result, manufacturers and distributors have reassessed sourcing strategies, shifting weight toward suppliers with nearshore capabilities or vertically integrated supply chains to reduce exposure to tariff volatility and shipping disruptions.
These adaptations have had ripple effects across procurement behavior in health systems. Pharmacy purchasing teams are placing added emphasis on contractual flexibility, contingency stock levels, and clearer escalation protocols with suppliers. Meanwhile, manufacturers with diversified manufacturing footprints and compliant, inspected fill-finish sites have been better positioned to absorb incremental duty costs or negotiate pass-through pricing with institutional buyers. Overall, the tariff-driven pressures of 2025 accelerated pre-existing trends toward supply chain resilience, encouraging stakeholders to prioritize continuity, regulatory compliance, and traceability amid evolving trade landscapes.
Strategic segmentation insights revealing how indications, routes, dosage forms, end-user settings, and patient cohorts uniquely influence clinical deployment and procurement of colistimethate sodium injection
Segmentation provides a structured lens to understand clinical use patterns, procurement drivers, and formulation preferences for colistimethate sodium injection. By indication, clinical demand is concentrated in bloodstream infections, which encompasses primary and secondary bacteremia presentations, and serious lower respiratory tract infections that include community-acquired, hospital-acquired, and ventilator-associated pneumonias. Skin and soft tissue infections represent another significant pool of clinical need, covering cellulitis, surgical site infections, and wound infections, while urinary tract infections are differentiated between complicated and uncomplicated presentations that influence dosing and duration decisions.
Route of administration segmentation highlights divergent operational implications: inhalation routes support adjunctive respiratory strategies, intramuscular options have niche applications, and intravenous use - whether by continuous infusion or intermittent infusion - remains the principal modality for systemic therapy. Dosage form distinctions between lyophilized powder and ready-to-use solutions affect pharmacy compounding demands and bedside readiness; within those families, multi-dose versus single-dose vials and infusion bag versus prefilled syringe configurations have distinct implications for waste, sterility practices, and inventory control. Finally, end-user segmentation spanning ambulatory care centers, outpatient and specialty clinics, general wards, and intensive care units, together with patient population stratifications across adult, geriatric, adolescent, child, infant, and neonatal cohorts, informs targeted clinical pathways and formulary placement decisions.
Regional dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory practices, supply chains, and clinical adoption of colistimethate sodium injection
Regional dynamics exert meaningful influence on regulatory pathways, supply chain architecture, and clinical adoption patterns for colistimethate sodium injection. In the Americas, hospital networks and academic medical centers play a leading role in defining clinical protocols and stewardship approaches, and North American supply chains emphasize regulatory compliance and inspected sterile fill-finish capacity. This region often drives rigorous post-authorization safety monitoring and formulary evaluations that influence global clinical practice.
Europe, Middle East & Africa presents a heterogeneous landscape where centralized procurement mechanisms coexist with fragmented national regulatory frameworks. In these markets, price sensitivity, national antimicrobial guidelines, and variable access to advanced compounding infrastructure shape how colistimethate sodium is procured and administered. Policymakers and regional health authorities in several jurisdictions are simultaneously prioritizing antimicrobial resistance containment programs and investments in hospital pharmacy capabilities. Asia-Pacific is characterized by rapid capacity expansion in sterile manufacturing, a growing emphasis on hospital-level adoption in tertiary care facilities, and diverse payer models. The region also demonstrates significant variation in clinical practice patterns, with several centers of excellence advancing combination therapy approaches and clinical research initiatives that inform global understanding of polymyxin use.
How manufacturers, contract providers, and clinical partners are aligning manufacturing resilience, formulation advancements, and evidence programs to strengthen supply and clinical adoption of injectable colistimethate sodium
Companies engaged with colistimethate sodium injectables are evolving along complementary strategic pathways centered on manufacturing reliability, formulation innovation, and partnerships with clinical stakeholders. Some organizations prioritize investments in sterile fill-finish capacity and quality systems to reduce lot-level variability and support rapid response to demand surges. Others focus on enhancing convenience and safety through development of ready-to-use solutions, prefilled syringes, or improved vial presentations that reduce preparation time and lower contamination risk.
Across the competitive landscape, contract development and manufacturing organizations have emerged as critical enablers, offering scalable sterile production and regulatory support for firms seeking to diversify supply. Commercial strategies increasingly combine evidence-generation programs, including real-world outcomes and pharmacokinetic/pharmacodynamic studies, with hospital education initiatives and stewardship collaborations to demonstrate safe, effective utilization. Firms that align manufacturing resilience with clinician-focused product features and robust safety communication are best positioned to sustain long-term institutional partnerships and uptake.
Practical strategic actions for manufacturers, distributors, and health systems to secure supply continuity, optimize clinical use, and accelerate adoption of higher-convenience formulations
Industry leaders should prioritize a set of actionable measures to safeguard supply continuity and enhance clinical utility of colistimethate sodium injection. First, diversify sourcing across multiple geographies and qualified suppliers, while advancing nearshore or regional fill-finish arrangements to reduce exposure to trade policy shocks and shipping constraints. Second, accelerate adoption of ready-to-use formulations and prefilled systems where clinically appropriate to streamline pharmacy workflow and improve patient safety, while ensuring compatibility with stewardship dosing protocols.
Third, invest in targeted evidence generation that addresses safety, dosing optimization, and real-world outcomes across defined patient cohorts, thereby supporting formulary acceptance and clinician confidence. Fourth, strengthen relationships with hospital pharmacy and infectious disease stakeholders through joint stewardship initiatives and operational pilots that quantify preparation time, waste reduction, and monitoring burden. Finally, incorporate flexible contracting terms and contingency inventory clauses into supplier agreements to provide procurement teams with practical tools for responding to episodic supply disruptions and evolving clinical demand patterns.
A transparent mixed-methods research approach integrating clinician and supply chain expert interviews with regulatory and clinical evidence synthesis to ensure robust and actionable insights
The research methodology combined structured primary engagements with subject-matter experts and a comprehensive secondary review of regulatory filings, clinical guidelines, pharmacovigilance databases, and peer-reviewed literature to create a robust evidence foundation. Primary inputs included interviews with infectious disease clinicians, hospital pharmacy directors, supply chain leads, and manufacturing quality experts to capture frontline experiences with dosing paradigms, preparation workflows, and supplier performance. These conversations were complemented by site visits and virtual facility assessments to validate manufacturing capabilities and quality systems.
Secondary analysis synthesized regulatory documents, label changes, clinical guidance statements, and published observational studies to contextualize real-world utilization and safety considerations. Data triangulation techniques ensured consistency across diverse inputs, and sensitivity checks were applied to reconcile differing stakeholder perspectives. Throughout the process, emphasis was placed on transparency of assumptions, traceability of source material, and documenting areas where evidence gaps remain, thereby enabling readers to understand the confidence and limitations associated with each analytical conclusion.
A concise conclusion highlighting the interplay of resistance, stewardship, and supply resilience that will determine the clinical availability and safe use of injectable colistimethate sodium
In summary, colistimethate sodium injection remains a vital therapeutic option in settings that confront multidrug-resistant Gram-negative infections, with clinical value shaped by indication-specific needs, route of administration choices, and dosage form preferences. The confluence of antimicrobial resistance pressures, evolving stewardship practices, and supply chain realignments underscores the need for proactive strategies that balance clinical efficacy with safety and operational efficiency. Stakeholders who invest in diversified sourcing, readiness for ready-to-use formulations, and collaborative evidence generation will be better equipped to navigate emerging challenges.
Looking ahead, the interplay between regional manufacturing capacity, regulatory requirements, and hospital-level stewardship programs will determine how readily available and safely administered colistimethate sodium remains as a treatment option. By aligning procurement strategies, clinical education, and formulation innovation, stakeholders can sustain access while optimizing patient outcomes and minimizing administration risk. The findings presented here are intended to guide operational decisions and clinical policy discussions grounded in contemporary practice and supply realities.
Note: PDF & Excel + Online Access - 1 Year
A comprehensive introduction that outlines the clinical role, formulation choices, and delivery considerations shaping colistimethate sodium injection utilization in modern care settings
Colistimethate sodium for injection occupies a critically important position in the therapeutic arsenal against multidrug-resistant Gram-negative infections. Clinically, it is deployed in severe bloodstream infections, complicated lower respiratory tract infections, challenging skin and soft tissue infections, and select urinary tract infections where alternative agents are ineffective or contraindicated. As resistance to contemporary beta-lactams and carbapenems has risen, clinicians have returned to older polymyxin-class agents like colistimethate sodium, balancing potent antibacterial activity against known safety considerations such as nephrotoxicity and neurotoxicity.
From a formulation and delivery perspective, the injectable product exists in multiple dosage forms and routes, which shape hospital administration practices and procurement preferences. Intravenous administration is predominant for systemic infections, whereas inhalation is increasingly used as an adjunctive approach in ventilator-associated complications. Additionally, distinctions between lyophilized powder that requires reconstitution and ready-to-use solutions influence pharmacy workflow and bedside efficiency. Taken together, these clinical, formulation, and delivery characteristics define the decision criteria for clinicians, pharmacy leaders, and purchasing groups evaluating the role of colistimethate sodium within treatment protocols.
How clinical resistance dynamics, stewardship protocols, and sterile manufacturing advances are reshaping therapeutic practice and procurement strategies for colistimethate sodium injection
The therapeutic and commercial landscape for colistimethate sodium injection is undergoing transformative shifts driven by antimicrobial resistance trends, evolving hospital practice standards, and innovations in sterile injectable manufacturing. Clinically, the expanding prevalence of carbapenem-resistant Enterobacterales and multidrug-resistant Acinetobacter species has elevated reliance on polymyxin-class therapies as salvage or combination regimens, prompting more frequent stewardship-led protocols that standardize dosing and monitoring to mitigate toxicity risks.
Operationally, hospitals and integrated delivery networks are accelerating adoption of ready-to-use infusion preparations and automated compounding technologies to reduce preparation time, limit contamination risk, and improve dosing accuracy. Concurrently, supply chain modernization - including strategic dual-sourcing, regional sterile fill-finish partnerships, and increased transparency around API origins - is reshaping procurement strategies. Regulatory scrutiny and post-marketing safety surveillance are also intensifying, with stakeholders demanding robust real-world evidence and pharmacovigilance data to support formulary decisions and optimize therapeutic pathways.
Analysis of how 2025 United States tariff changes have compounded supply chain, sourcing, and procurement dynamics affecting colistimethate sodium injection availability and commercial strategies
Cumulative adjustments to United States tariff schedules and related trade policy changes enacted through 2025 have created a layered impact on the injectable pharmaceuticals ecosystem that includes colistimethate sodium. Increased duties on select active pharmaceutical ingredients and intermediates, combined with higher freight and compliance-associated costs, have elevated landed costs for some producers that rely on globally distributed supply chains. As a result, manufacturers and distributors have reassessed sourcing strategies, shifting weight toward suppliers with nearshore capabilities or vertically integrated supply chains to reduce exposure to tariff volatility and shipping disruptions.
These adaptations have had ripple effects across procurement behavior in health systems. Pharmacy purchasing teams are placing added emphasis on contractual flexibility, contingency stock levels, and clearer escalation protocols with suppliers. Meanwhile, manufacturers with diversified manufacturing footprints and compliant, inspected fill-finish sites have been better positioned to absorb incremental duty costs or negotiate pass-through pricing with institutional buyers. Overall, the tariff-driven pressures of 2025 accelerated pre-existing trends toward supply chain resilience, encouraging stakeholders to prioritize continuity, regulatory compliance, and traceability amid evolving trade landscapes.
Strategic segmentation insights revealing how indications, routes, dosage forms, end-user settings, and patient cohorts uniquely influence clinical deployment and procurement of colistimethate sodium injection
Segmentation provides a structured lens to understand clinical use patterns, procurement drivers, and formulation preferences for colistimethate sodium injection. By indication, clinical demand is concentrated in bloodstream infections, which encompasses primary and secondary bacteremia presentations, and serious lower respiratory tract infections that include community-acquired, hospital-acquired, and ventilator-associated pneumonias. Skin and soft tissue infections represent another significant pool of clinical need, covering cellulitis, surgical site infections, and wound infections, while urinary tract infections are differentiated between complicated and uncomplicated presentations that influence dosing and duration decisions.
Route of administration segmentation highlights divergent operational implications: inhalation routes support adjunctive respiratory strategies, intramuscular options have niche applications, and intravenous use - whether by continuous infusion or intermittent infusion - remains the principal modality for systemic therapy. Dosage form distinctions between lyophilized powder and ready-to-use solutions affect pharmacy compounding demands and bedside readiness; within those families, multi-dose versus single-dose vials and infusion bag versus prefilled syringe configurations have distinct implications for waste, sterility practices, and inventory control. Finally, end-user segmentation spanning ambulatory care centers, outpatient and specialty clinics, general wards, and intensive care units, together with patient population stratifications across adult, geriatric, adolescent, child, infant, and neonatal cohorts, informs targeted clinical pathways and formulary placement decisions.
Regional dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory practices, supply chains, and clinical adoption of colistimethate sodium injection
Regional dynamics exert meaningful influence on regulatory pathways, supply chain architecture, and clinical adoption patterns for colistimethate sodium injection. In the Americas, hospital networks and academic medical centers play a leading role in defining clinical protocols and stewardship approaches, and North American supply chains emphasize regulatory compliance and inspected sterile fill-finish capacity. This region often drives rigorous post-authorization safety monitoring and formulary evaluations that influence global clinical practice.
Europe, Middle East & Africa presents a heterogeneous landscape where centralized procurement mechanisms coexist with fragmented national regulatory frameworks. In these markets, price sensitivity, national antimicrobial guidelines, and variable access to advanced compounding infrastructure shape how colistimethate sodium is procured and administered. Policymakers and regional health authorities in several jurisdictions are simultaneously prioritizing antimicrobial resistance containment programs and investments in hospital pharmacy capabilities. Asia-Pacific is characterized by rapid capacity expansion in sterile manufacturing, a growing emphasis on hospital-level adoption in tertiary care facilities, and diverse payer models. The region also demonstrates significant variation in clinical practice patterns, with several centers of excellence advancing combination therapy approaches and clinical research initiatives that inform global understanding of polymyxin use.
How manufacturers, contract providers, and clinical partners are aligning manufacturing resilience, formulation advancements, and evidence programs to strengthen supply and clinical adoption of injectable colistimethate sodium
Companies engaged with colistimethate sodium injectables are evolving along complementary strategic pathways centered on manufacturing reliability, formulation innovation, and partnerships with clinical stakeholders. Some organizations prioritize investments in sterile fill-finish capacity and quality systems to reduce lot-level variability and support rapid response to demand surges. Others focus on enhancing convenience and safety through development of ready-to-use solutions, prefilled syringes, or improved vial presentations that reduce preparation time and lower contamination risk.
Across the competitive landscape, contract development and manufacturing organizations have emerged as critical enablers, offering scalable sterile production and regulatory support for firms seeking to diversify supply. Commercial strategies increasingly combine evidence-generation programs, including real-world outcomes and pharmacokinetic/pharmacodynamic studies, with hospital education initiatives and stewardship collaborations to demonstrate safe, effective utilization. Firms that align manufacturing resilience with clinician-focused product features and robust safety communication are best positioned to sustain long-term institutional partnerships and uptake.
Practical strategic actions for manufacturers, distributors, and health systems to secure supply continuity, optimize clinical use, and accelerate adoption of higher-convenience formulations
Industry leaders should prioritize a set of actionable measures to safeguard supply continuity and enhance clinical utility of colistimethate sodium injection. First, diversify sourcing across multiple geographies and qualified suppliers, while advancing nearshore or regional fill-finish arrangements to reduce exposure to trade policy shocks and shipping constraints. Second, accelerate adoption of ready-to-use formulations and prefilled systems where clinically appropriate to streamline pharmacy workflow and improve patient safety, while ensuring compatibility with stewardship dosing protocols.
Third, invest in targeted evidence generation that addresses safety, dosing optimization, and real-world outcomes across defined patient cohorts, thereby supporting formulary acceptance and clinician confidence. Fourth, strengthen relationships with hospital pharmacy and infectious disease stakeholders through joint stewardship initiatives and operational pilots that quantify preparation time, waste reduction, and monitoring burden. Finally, incorporate flexible contracting terms and contingency inventory clauses into supplier agreements to provide procurement teams with practical tools for responding to episodic supply disruptions and evolving clinical demand patterns.
A transparent mixed-methods research approach integrating clinician and supply chain expert interviews with regulatory and clinical evidence synthesis to ensure robust and actionable insights
The research methodology combined structured primary engagements with subject-matter experts and a comprehensive secondary review of regulatory filings, clinical guidelines, pharmacovigilance databases, and peer-reviewed literature to create a robust evidence foundation. Primary inputs included interviews with infectious disease clinicians, hospital pharmacy directors, supply chain leads, and manufacturing quality experts to capture frontline experiences with dosing paradigms, preparation workflows, and supplier performance. These conversations were complemented by site visits and virtual facility assessments to validate manufacturing capabilities and quality systems.
Secondary analysis synthesized regulatory documents, label changes, clinical guidance statements, and published observational studies to contextualize real-world utilization and safety considerations. Data triangulation techniques ensured consistency across diverse inputs, and sensitivity checks were applied to reconcile differing stakeholder perspectives. Throughout the process, emphasis was placed on transparency of assumptions, traceability of source material, and documenting areas where evidence gaps remain, thereby enabling readers to understand the confidence and limitations associated with each analytical conclusion.
A concise conclusion highlighting the interplay of resistance, stewardship, and supply resilience that will determine the clinical availability and safe use of injectable colistimethate sodium
In summary, colistimethate sodium injection remains a vital therapeutic option in settings that confront multidrug-resistant Gram-negative infections, with clinical value shaped by indication-specific needs, route of administration choices, and dosage form preferences. The confluence of antimicrobial resistance pressures, evolving stewardship practices, and supply chain realignments underscores the need for proactive strategies that balance clinical efficacy with safety and operational efficiency. Stakeholders who invest in diversified sourcing, readiness for ready-to-use formulations, and collaborative evidence generation will be better equipped to navigate emerging challenges.
Looking ahead, the interplay between regional manufacturing capacity, regulatory requirements, and hospital-level stewardship programs will determine how readily available and safely administered colistimethate sodium remains as a treatment option. By aligning procurement strategies, clinical education, and formulation innovation, stakeholders can sustain access while optimizing patient outcomes and minimizing administration risk. The findings presented here are intended to guide operational decisions and clinical policy discussions grounded in contemporary practice and supply realities.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
- 2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
- 3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
- 4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Porter’s Five Forces Analysis
- 4.4. PESTLE Analysis
- 4.5. Market Outlook
- 4.5.1. Near-Term Market Outlook (0–2 Years)
- 4.5.2. Medium-Term Market Outlook (3–5 Years)
- 4.5.3. Long-Term Market Outlook (5–10 Years)
- 4.6. Go-to-Market Strategy
- 5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Colistimethate Sodium for Injection Market, by Indication
- 8.1. Bloodstream Infection
- 8.1.1. Primary Bacteremia
- 8.1.2. Secondary Bacteremia
- 8.2. Lower Respiratory Tract Infection
- 8.2.1. Community Acquired Pneumonia
- 8.2.2. Hospital Acquired Pneumonia
- 8.2.3. Ventilator Associated Pneumonia
- 8.3. Skin And Soft Tissue Infection
- 8.3.1. Cellulitis
- 8.3.2. Surgical Site Infection
- 8.3.3. Wound Infection
- 8.4. Urinary Tract Infection
- 8.4.1. Complicated Urinary Tract Infection
- 8.4.2. Uncomplicated Urinary Tract Infection
- 9. Colistimethate Sodium for Injection Market, by Dosage Form
- 9.1. Lyophilized Powder
- 9.1.1. Multi Dose Vial
- 9.1.2. Single Dose Vial
- 9.2. Ready To Use Solution
- 9.2.1. Infusion Bag
- 9.2.2. Prefilled Syringe
- 10. Colistimethate Sodium for Injection Market, by Patient Population
- 10.1. Adult
- 10.2. Geriatric
- 10.3. Pediatric
- 10.3.1. Adolescent
- 10.3.2. Child
- 10.3.3. Infant
- 10.3.4. Neonatal
- 11. Colistimethate Sodium for Injection Market, by Route Of Administration
- 11.1. Inhalation
- 11.2. Intramuscular
- 11.3. Intravenous
- 11.3.1. Continuous Infusion
- 11.3.2. Intermittent Infusion
- 12. Colistimethate Sodium for Injection Market, by End User
- 12.1. Ambulatory Care Center
- 12.2. Clinic
- 12.2.1. Outpatient Clinic
- 12.2.2. Specialty Clinic
- 12.3. Hospital
- 12.3.1. General Ward
- 12.3.2. Intensive Care Unit
- 13. Colistimethate Sodium for Injection Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Colistimethate Sodium for Injection Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Colistimethate Sodium for Injection Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. United States Colistimethate Sodium for Injection Market
- 17. China Colistimethate Sodium for Injection Market
- 18. Competitive Landscape
- 18.1. Market Concentration Analysis, 2025
- 18.1.1. Concentration Ratio (CR)
- 18.1.2. Herfindahl Hirschman Index (HHI)
- 18.2. Recent Developments & Impact Analysis, 2025
- 18.3. Product Portfolio Analysis, 2025
- 18.4. Benchmarking Analysis, 2025
- 18.5. Abbott
- 18.6. Fresenius Kabi AG
- 18.7. Gland Pharma Limited
- 18.8. Hikma Pharmaceuticals PLC
- 18.9. Lupin Limited
- 18.10. Pfizer Inc.
- 18.11. Sagent Pharmaceuticals, Inc.
- 18.12. Sandoz International GmbH
- 18.13. Teva Pharmaceutical Industries Ltd.
- 18.14. Viatris Inc.
- 18.15. Zydus Lifesciences Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
